BCC Research says AI-backed cardiovascular drug development draws over $1.4 billion

The BCC Pulse report says regulators are becoming more receptive to digital health tools and real-world data, potentially easing pathways for AI use in cardiovascular drug trials and safety monitoring.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.